新生儿重症监护病房抗生素与结局(NANO)试验:一项评估经验性抗生素与临床结局的随机多中心临床试验
NANO试验是一项多中心、双盲、随机对照试验,计划纳入802例胎龄≤29周的超低出生体重早产儿,随机接受经验性抗生素(氨苄西林联合庆大霉素)或安慰剂,主要结局为住院期间坏死性小肠结肠炎、晚发型脓毒症或死亡的复合发生率,并纵向采集母婴样本评估微生物组差异。
要点
- 超低出生体重儿早发型脓毒症总体发生率约为2-3%,但常经验性使用广谱抗生素。
- 观察性研究提示围产期抗生素使用与坏死性小肠结肠炎、晚发型脓毒症和死亡发生率增加相关。
- NANO试验旨在确定超低出生体重儿早期经验性抗生素使用的安全性。
核心结论
- NANO试验旨在比较超低出生体重早产儿出生时经验性抗生素使用与安慰剂的不良结局发生率。
- 若经验性抗生素使临床结局恶化,结果可能帮助减少新生儿重症监护病房抗生素使用及早期抗生素相关并发症。
- 若经验性抗生素改善结局,该试验将验证此前缺乏高质量数据支持的长期临床实践。
研究设计与样本
- 多中心、双盲、随机对照试验,计划样本量为802例超低出生体重早产儿。
- 通过基于网络的分层区组随机化,分配至经验性抗生素组(氨苄西林和庆大霉素)或安慰剂组,在早发型脓毒症常规评估期间给药。
- 参与中心使用既有的机构方案决定抗生素剂量和疗程。
- 纳入标准为在参与中心出生且胎龄≤29周的婴儿。
- 排除标准包括母亲宫内感染、血流动力学或呼吸不稳定、因母亲指征行剖宫产且无产程或胎膜早破时间不长、以及既往使用过抗生素。
主要发现
- 主要结局为参与者索引住院期间坏死性小肠结肠炎、晚发型脓毒症或死亡的复合发生率。
- 将纵向采集母婴样本,评估微生物组组成和多样性的差异。
关键数值与推荐
- 超低出生体重儿早发型脓毒症总体发生率约为2-3%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early-onset sepsis is an important cause of neonatal morbidity and mortality in the preterm population. Infants perceived to be at increased risk for early-onset sepsis are often treated empirically with broad-spectrum antibiotics while awaiting confirmatory blood cultures, despite an overall incidence of early-onset sepsis of 2-3% among extremely-low-birthweight (ELBW) infants. Recent observational studies associate perinatal antibiotic use with an increased incidence of necrotizing enterocolitis, late-onset sepsis, and mortality among ELBW infants. Given currently available data and variability in clinical practice, we designed a prospective multi-institutional randomized controlled trial to determine the safety of early antibiotic use in ELBW infants. METHODS: The NICU Antibiotics and Outcomes (NANO) trial is a multicenter, double-blinded, randomized controlled trial. A sample of 802 ELBW preterm infants will undergo web-based stratified block randomization to receive empiric antibiotics (EA; ampicillin and gentamicin) or placebo during routine evaluation for early-onset sepsis. Participating sites will use preexisting institutional protocols for antibiotic dosage and duration. Infants born at participating sites with a gestational age of 29 weeks or less are eligible for enrollment. Exclusion criteria include maternal intrauterine infection, hemodynamic or respiratory instability, delivery by caesarean section for maternal indications without labor or prolonged rupture of membranes, and prior administration of antibiotics. The primary outcome is the composite incidence of necrotizing enterocolitis, late-onset sepsis, or death during participants' index hospitalization. Maternal and infant samples will be collected longitudinally and assessed for differences in microbiome composition and diversity. DISCUSSION: The NANO trial is designed to compare the rate of adverse outcomes of EA use at birth versus placebo in ELBW preterm infants. If EA at birth worsens clinical outcomes, then the results of the trial may help providers decrease antibiotic utilization in the NICU and subsequently decrease the incidence of complications associated with early antibiotic use in ELBW infants. If we instead find that EA improve outcomes, then the trial will validate a longstanding clinical practice that has not previously been supported by high-quality data. Future studies will assess long-term clinical and microbial outcomes in infants who received empiric antibiotics following delivery. TRIAL REGISTRATION: Trial registration data: June 25, 2019 NCT03997266 .
引用
- Morowitz MJ, Katheria AC, Polin RA, et al. The NICU Antibiotics and Outcomes (NANO) trial: a randomized multicenter clinical trial assessing empiric antibiotics and clinical outcomes in newborn preterm infants. Trials. 2022. PMID: 35606829. doi:10.1186/s13063-022-06352-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。